VERACYTE, INC.

Public Equity (NASDAQ)DiagnosticsGenomicsPublic

📍 South San Francisco, CA, USA• Founded 2008

StreetZero Signal 61

Be the first to signal interest

About VERACYTE, INC.

Veracyte, Inc. is a genomic diagnostics company that develops and commercializes molecular tests to improve the diagnosis and treatment of thyroid, lung, breast and other cancers. The company leverages its proprietary Afirma, Percepta and Envisia tests along with its whole-transcriptome sequencing platform to help physicians reduce unnecessary surgeries and improve patient outcomes. Headquartered in South San Francisco, California, Veracyte operates in the United States and internationally.

LATEST FUNDINGRule 144

$716K

Announced 2026-10-27

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for VERACYTE, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED2008

HQSouth San Francisco, CA, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Raised $715,770 via Rule 144 private placement
Publicly traded on NASDAQ under VCYT
Focuses on cancer genomic testing
Located in South San Francisco, CA

Ask StreetZero about VERACYTE, INC.

Put our AI to work on this deal.

What is VERACYTE, INC.'s value proposition?Who are VERACYTE, INC.'s competitors?Why does this raise matter?Summarize VERACYTE, INC. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.